共 50 条
- [31] Reduction in Acute Filariasis Morbidity during a Mass Drug Administration Trial to Eliminate Lymphatic Filariasis in Papua New Guinea [J]. PLOS NEGLECTED TROPICAL DISEASES, 2011, 5 (07):
- [32] Pharmacokinetics, feasibility and safety of co-administering azithromycin, albendazole, and ivermectin during mass drug administration: A review [J]. PLOS NEGLECTED TROPICAL DISEASES, 2023, 17 (06):
- [33] DECLINING MASS DRUG ADMINISTRATION COVERAGE FOR LYMPHATIC FILARIASIS IN PORT-AU-PRINCE, HAITI: A PROGRAMMATIC CASE STUDY AND RECOMMENDATIONS [J]. AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2019, 101 : 400 - 400
- [34] COMMUNITY RANDOMIZED SAFETY TRIAL OF TRIPLE- DRUG MASS DRUG ADMINISTRATION FOR LYMPHATIC FILARIASIS IN PAPUA NEW GUINEA [J]. AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2017, 97 (05): : 239 - 239
- [35] Factors Influencing Drug Uptake during Mass Drug Administration for Control of Lymphatic Filariasis in Rural and Urban Tanzania [J]. PLOS ONE, 2014, 9 (10):
- [37] The fight against lymphatic filariasis: perceptions of community drug distributors during mass drug administration in coastal Kenya [J]. Infectious Diseases of Poverty, 9
- [39] THE IMPACT OF MASS DRUG ADMINISTRATION WITH A TRIPLE DRUG REGIMEN (IVERMECTIN, DIETHYLCARBAMAZINE AND ALBENDAZOLE) ON LYMPHATIC FILARIASIS IN PAPUA NEW GUINEA AND IMPLICATIONS FOR POST-MDA SURVEILLANCE [J]. AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2021, 105 (05): : 138 - 138
- [40] Mass drug administration of ivermectin, diethylcarbamazine, plus albendazole compared with diethylcarbamazine plus albendazole for reduction of lymphatic filariasis endemicity in Papua New Guinea: a cluster-randomised trial [J]. LANCET INFECTIOUS DISEASES, 2022, 22 (08): : 1200 - 1209